この記事を読む

肺癌治療の進歩にもかかわらず、まだ気管支漏には対処が難しい

Bronchorrhea, a Rare and Debilitating Symptom of Lung Cancer: Case Report and Review of the Treatment. Bhagat M et al.JT…

この記事を読む

PETによる原発巣と転移巣の効果判定の不一致

18F-FDG PET/CT for assessing heterogeneous metabolic response between primary tumor and metastases and prognosis in non-…

この記事を読む

ペムブロリズマブ3週から6週間隔への変更でirAEが増える可能性

Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With…

この記事を読む

小細胞肺癌に対する免疫療法の実地データ

Real-world evidence for immunotherapy in the first line setting in small cell lung cancer Shira Sagie et al.lung Cancer …

この記事を読む

ヒスパニック系におけるオシメルチニブの耐性機序

Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRE…

この記事を読む

低分化型腺癌と腫瘍微小環境との関連

Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic t…

この記事を読む

ALK/ROS1陽性は血栓塞栓症のリスクが高い

Common genetic driver mutation in NSCLC and their association with thromboembolic events: A retrospective study. Lin M e…

この記事を読む

KEYNOTE-091、術後補助化学療法後のペムブロリズマブ、解釈が難しい

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-ⅢA non-small-cell lung cancer (PEARLS/…

この記事を読む

オシメルチニブ+ベバシズマブは喫煙者向き?

Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCL…

この記事を読む

定位放射線治療:一回照射の注意点

Practical considerations of single-fraction stereotactic ablative radiotherapy to the lung. Kang TM et al.Lung Cancer. 2…